209 filings
Page 3 of 11
CORRESP
vlcil2csw91iqksq rlc
3 May 23
Correspondence with SEC
12:00am
CORRESP
9tg blqqj6beofq
3 May 23
Correspondence with SEC
12:00am
CORRESP
6iuxgqzf k8me
3 May 23
Correspondence with SEC
12:00am
D
2jyzlhhuq4e53ux6
14 Apr 23
Indefinite amount in options / securities to be acquired, 9 investors
5:00pm
UPLOAD
rop fl1dri
14 Apr 23
Letter from SEC
12:00am
8-K
4r679riztlgd1ymfm
4 Apr 23
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
6:05am
424B5
cufe1pbk2nkr8h2m
4 Apr 23
Prospectus supplement for primary offering
6:03am
8-K
qpsp0f9dj
31 Mar 23
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
6:00am
8-K
b39s3yel
10 Mar 23
Regulation FD Disclosure
5:07pm
D
3capha zld0uhos
3 Mar 23
Indefinite amount in options / securities to be acquired, 1 investor
5:15pm
8-K
7p1ma3pl gc6s
2 Mar 23
FDA indicates that it does not currently plan to hold an advisory committee meeting
7:30am
8-K
i3jwk5i0d l9k
22 Feb 23
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
5:00pm
424B5
tmjbr afvl
22 Feb 23
Prospectus supplement for primary offering
4:56pm
8-K
8mabfah0fvjc o1bh
4 Jan 23
Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications
8:30am